ClinicalTrials.gg
CompletedNCT03601221Updated Mar 31, 2020

Seroprevalence Hepatitis E Infection in Healthy Blood Donors

An observational study in Hepatitis E, sponsored by Ente Ospedaliero Cantonale, Bellinzona. Completed at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2020-03-31.

Sponsored by Ente Ospedaliero Cantonale, Bellinzona · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,447
Sex
All
01

Study summary

This is a HEV seroprevalence in the health donors in the Canton Ticino study. The pre-donation sampling pouch of each blood donor coming form the Cantone Ticino region will be collected and tested for HEV serology (IgM and IgG).

Read the detailed description

Pre-donation sampling pouch of fresh and stored frozen plasma collected within the last 5 years will be tested for HEV IgG serology at the National Reference Laboratory of the Blood Transfusion Services SRC in Berne Collected data will be used to determine HEV seroprevalence, actual and in the last 5 years, in the Canton Ticino and to investigate trend and pattern of the HEV infection (seroprevalence by different regional areas, comparison with national HEV data, and correlation with age, sex and place of residence).

02

Conditions studied

  • Hepatitis E

Browse trials for

03

In context

Hepatitis E

37 studies on the registry are indexed under Hepatitis E; 9 are open to participants now.

This study's enrollment of 1,447 is above the median of 436 across 11 observational studies indexed under Hepatitis E.

Browse Hepatitis E studies →

Lead sponsor

Ente Ospedaliero Cantonale, Bellinzona is the lead sponsor of 38 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Healthy and voluntary blood donors

Eligibility criteria

Inclusion Criteria:

  • Healthy and voluntary blood donors
  • Subjects living in the Canton Ticino
  • Inclusion criteria for blood donation
  • Signed of the STCRS SI for blood donation

Exclusion Criteria:

  • Exclusion criteria for blood donation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,447 participants (actual)
Patient registry
No

Interventions

  • OtherSample collection

    Collection of one sampling pouch from each blood donor

06

What researchers measure

Primary outcomes

  1. HEV blood incidence

    HEV incidence assessed through a single periferal blood sample from each donor

    Time frame: One year

Secondary outcomes

  1. change in the blood incidence of HEV

    Determine the change in the incidence of HEV in the Canton Ticino region in the last 5 years analysing the blood sample of the donors.

    Time frame: Five years

  2. Geogarphical distribution of the HEV measured in the blood sample

    Determination of the distribution of the HEV infection in different geographical areas of the Canton Ticino analysing donor blood samples

    Time frame: Five years

  3. Trend of the HEV infection measured in the blood sample

    Evaluation of the trend of the HEV infection in the CantoneTicino compared to other Swiss cantons

    Time frame: One year

07

Study locations

1 site
  • Swiss Transfusion SRC Canton Ticino
    Lugano,, 6900, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03601221
Lead sponsor
Ente Ospedaliero Cantonale, Bellinzona
Collaborators
Swiss Transfusion SRC, Clinical Trial Unit Ente Ospedaliero Cantonale
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
May 29, 2018
Primary completion
Dec 31, 2018
Completion
Dec 31, 2019
Last update
Mar 31, 2020

Study contacts

Florian Bihl, MD
study director · Ente Ospedaliero Cantonale, Bellinzona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion